Want to see HEWA full AI Analyst Report?
HealthWarehouse (HEWA) AI Stock Analysis
Top Page
HealthWarehouse
(Other OTC:HEWA)
The overall score is very low, driven primarily by the company's dire financial state, which includes technical insolvency, a sharp revenue decline, and negative cash flows. While short-term technicals show some positive momentum, this is overshadowed by the fundamental risk of financial distress. The negative P/E ratio further confirms the lack of earnings power, making the stock highly speculative.
HealthWarehouse (HEWA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 33.40K
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- -0.40
- Revenue Growth
- -42.51%
- EPS Growth
- -481.03%
- Country
- US
- Employees
- 121
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
HealthWarehouse Business Overview & Revenue Model
Company Description
HealthWarehouse.com, Inc. functions as a digital and direct-mail pharmaceutical service. Its offerings encompass a broad spectrum of pharmaceutical items, including generic and brand-name prescription drugs, specialized medications for pets, and a va...
HealthWarehouse Financial Statement Overview
Summary
Financial health is critically poor. The income statement shows severe deterioration with collapsing margins and a swing to net losses. The balance sheet is technically insolvent with negative equity, and cash flow has turned negative, indicating a cash burn. This combination of operational losses, a fragile balance sheet, and negative cash flow represents a high-risk, distressed financial profile.
Income Statement
18Very NegativeBalance Sheet
8Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.73M | 48.99M | 33.61M | 20.28M | 18.14M | 16.14M |
| Gross Profit | 14.09M | 17.14M | 13.69M | 12.17M | 11.94M | 11.13M |
| EBITDA | -292.08K | 931.62K | 338.42K | -1.28M | -559.33K | -224.76K |
| Net Income | -915.87K | 265.00K | -332.97K | -1.77M | -952.03K | -572.50K |
Balance Sheet | ||||||
| Total Assets | 4.57M | 5.88M | 5.05M | 3.21M | 3.97M | 3.62M |
| Cash, Cash Equivalents and Short-Term Investments | 1.07M | 2.21M | 1.13M | 567.96K | 1.04M | 2.18M |
| Total Debt | 3.52M | 2.90M | 3.84M | 2.09M | 3.04M | 2.15M |
| Total Liabilities | 8.53M | 9.18M | 9.08M | 7.21M | 7.00M | 6.41M |
| Stockholders Equity | -3.95M | -3.30M | -4.04M | -4.01M | -3.03M | -2.79M |
Cash Flow | ||||||
| Free Cash Flow | -843.05K | 1.06M | 565.36K | -473.81K | -1.14M | 313.64K |
| Operating Cash Flow | -783.85K | 1.16M | 705.26K | -163.84K | -624.45K | 400.51K |
| Investing Cash Flow | -59.20K | -95.23K | -139.90K | -309.97K | -512.85K | -86.86K |
| Financing Cash Flow | 0 | 9,000 | 0 | 0 | 0 | 0 |
HealthWarehouse Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HEWA, the sentiment is Neutral. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 53.59 is Neutral, neither overbought nor oversold. The STOCH value of 94.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HEWA.
HealthWarehouse Peers Comparison
Overall Rating
HSCS49Neutral
PETS48Neutral
LFMD44Neutral- HEWA43.7Neutral
NDRA34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HSCS | 49Neutral | $16.45M | -1.03 | -816.25% | ― | -27.70% | 61.44% |
| PETS | 48Neutral | $25.80M | -0.86 | -91.67% | ― | -19.67% | 34.91% |
| LFMD | 44Neutral | $110.38M | -4.51 | -179.12% | ― | -16.73% | -143.95% |
| HEWA | 44Neutral | $5.14M | -4.28 | 25.60% | ― | -42.51% | -481.03% |
| NDRA | 34Underperform | $7.12M | -0.75 | -224.80% | ― | ― | 98.17% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HEWA | HealthWarehousecom | 0.09 | -0.06 | -40.27% | |
| PETS | Petmed Express | 1.19 | -1.25 | -51.23% | |
| NDRA | Endra Life Sciences | 4.75 | -0.42 | -8.12% | |
| LFMD | Lifemd, Inc. | 2.29 | -3.45 | -60.10% | |
| KTTA | Pasithea Therapeutics Corp. | 0.37 | -0.45 | -54.88% | |
| HSCS | Heart Test Laboratories, Inc. | 3.31 | 0.38 | 12.97% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026